JGJulia Christine Gutjahr

Julia Christine Gutjahr

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Julia Christine Gutjahr has a total of 140 co-authors. Here are the top co-authors by number of shared publications:

  • Tanja Nicole Hartmann

    Department of Medicine I, Medical Center-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany

    8 shared publications
  • Richard Greil

    Department of Internal Medicine III with Hematology, Medical Oncology, Haemostaseology; Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute-Laboratory for Immunological and Molecular Cancer Research, Paracelsus Medical University, Cancer Cluster Salzburg, Salzburg, Austria

    6 shared publications
  • Antal Rot

    Centre for Microvascular Research The William Harvey Research Institute, Queen Mary University of London London UK

    5 shared publications
  • Elin Hub

    Faculty of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom

    4 shared publications
  • Alexander Egle

    Cancer Research Laboratory of the 3rd Medical University Department for Hematology, Medical Oncology, Hemostaseology, Infectious Disease and Rheumatology, Paracelsus Medical University, Salzburg, Austria

    3 shared publications
  • Andrea Härzschel

    Department of Internal Medicine I, Medical Center and Faculty of Medicine, University of Freiburg

    3 shared publications

Latest Publications

  • Open Access

    Erythroid Atypical Chemokine Receptor 1 Deficiency Aggravates Immune-Mediated Kidney Disease

    by Katharina Artinger, Igor Novitzky-Basso, Konstantin A. Klötzer, Nathaly Anto-Michel, Corinna Schabhüttl, Julia Christine Gutjahr, Maryna Samus, Elin Hub, Alexander H. Kirsch, Daniel Leitinger, et al.

    Key Points: Selective erythroid atypical chemokine receptor 1 deficiency exacerbated disease activity in experimental GN via changes of the myeloid lineage. Activated monocytes and profibrogenic phenotypes of macrophages underlaid the kidney phenotype observed in erythroid-silent individuals. Genetically modified mouse models showed pathomechanisms of kidney diseases in patients of West African ancestry with erythroid atypical chemokine receptor 1 deficiency. Background: Single-nucleotide polymorphisms of the atypical chemokine receptor 1 ( ACKR1 ) gene encode human Duffy antigen blood groups. Most individuals of West African ancestry carry a single-nucleotide polymorphism in the promoter region of the ACKR1 gene that disrupts its transcription in erythroid cells but not in venular endothelial cells, leading to an erythroid-silent, FyBES Duffy phenotype. Methods: We used two mouse models of erythroid-selective ACKR1 deficiency to delineate the fundamental role of this receptor in the erythroid compartment in regulating the development of experimental immune-mediated kidney disease. Results: Humanized transgenic Duffy erythroid-silent Duffy-negative transgene mice and chimeric wild-type mice transplanted with ACKR1-deficient bone marrow, both selectively lacking erythroid ACKR1, showed increased disease activity and fibrosis after induction of nephrotoxic serum nephritis, as compared with their respective controls. Mice lacking erythroid ACKR1 exhibited altered serum chemokine levels and bone marrow monocytes displaying activated and promigratory phenotypes. Moreover, they showed an increase in kidney-infiltrating macrophages that were characterized by a profibrotic transcriptome signature. No changes in ACKR1 expression in kidney vascular endothelial cells were seen in erythroid ACKR1-deficient mice with or without nephrotoxic serum nephritis. Conclusions: Our data demonstrates that erythroid-specific ACKR1 deficiency led to an increased infiltration of the kidney by macrophages with an altered profibrotic phenotype in nephrotoxic serum nephritis, resulting in aggravated kidney disease.


  • Intracellular and nuclear CXCR4 signaling promotes terminal erythroblast differentiation and enucleation

    by Julia Christine Gutjahr, Elin Hub, Caroline Amy Anderson, Maryna Samus, Katharina Artinger, Esteban A. Gomez, Christoph Ratswohl, Natalie Wickli, Mandy Raum, Neil Dufton, et al.

    The chemokine CXCL12 signals through its receptor CXCR4 to induce the migration of all leukocyte types and multiple other cell types. Here, we report that CXCR4 is expressed in mouse erythroblasts, the bone marrow erythroid precursors, in which it stimulates erythrocyte generation instead of chemotaxis. CXCR4 signaling promoted homeostatic erythroblast maturation and increased the expression of genes mainly involved in metabolism and chromatin organization. Consequently, genetic depletion of CXCR4 in erythroblasts inhibited late erythropoiesis and diminished bone marrow erythroid outputs. Binding of CXCL12 to CXCR4 stimulated its rapid endocytosis and translocation together with Gα i or phosphorylated β-arrestin1 into distinct intracellular compartments, including the nuclear envelope and nucleus. CXCL12 signaling promoted erythroblast elongation and the condensation and excentric positioning of nuclei and stimulated rapid perinuclear Ca 2+ transients that immediately preceded erythroblast enucleation. These findings highlight previously uncharacterized physiological roles for CXCR4 and bone marrow–derived CXCL12 in erythropoiesis.


  • Open Access

    Intracellular and nuclear CXCR4 signaling promotes erythroblast enucleation

    by Julia Gutjahr, Elin Hub, Caroline Anderson, Maryna Samus, Katharina Artinger, Neil Dufton, Jemima Burden, Johan Duchene, Antal Rot

    All leukocytes express chemokine receptor CXCR4 on their surface and efficiently migrate in response to its sole ligand CXCL12. Here we report for the first time that CXCR4 is also prominently expressed in erythroblasts, the bone marrow erythroid precursor cells but, instead of chemotaxis, CXCR4 signaling promoted erythroblast enucleation, a unique mammalian process of their asymmetrical division into an anuclear reticulocyte and a nucleus-containing pyrenocyte. Mechanistically, CXCL12 ligation of erythroblast CXCR4 triggered its endocytosis and translocation into multiple intracellular compartments. These included, surprisingly, the nuclear envelope and nucleus where CXCL12 and CXCR4 colocalized with either Gαi or phosphorylated β-arrestin1, respectively, suggesting an ongoing differential CXCR4 signaling around and within the erythroblast nucleus. Supporting the notion of intracellular signaling, stimulation of erythroblasts with CXCL12 caused a persistent phosphorylation of intracellular and intranuclear CXCR4 and a delayed activation of multiple protein kinases. Furthermore, CXCL12 induced erythroblast elongation, a condensation and ex-centric positioning of their nuclei and triggered rapid perinuclear Ca2+ transients, which led directly to erythroblast enucleation. The CXCR4-mediated sequential erythroblast responses taking place during ultimate steps of their development and culminating in enucleation pinpoint a new physiological role of CXCR4 and the bone marrow-derived CXCL12 in regulating erythrocyte production.

  • The dimeric form of CXCL12 binds to atypical chemokine receptor 1

    by Julia C. Gutjahr, Kyler S. Crawford, Davin R. Jensen, Prachi Naik, Francis C. Peterson, Guerric P. B. Samson, Daniel F. Legler, Johan Duchene, Christopher T. Veldkamp, Antal Rot, et al.

    Biological functions of CXCL12 dimers may be modified by the atypical receptor ACKR1.


  • Open Access

    Expression of ACKR4 demarcates the “peri-marginal sinus,” a specialized vascular compartment of the splenic red pulp

    by Kathrin Werth, Elin Hub, Julia Christine Gutjahr, Berislav Bosjnak, Xiang Zheng, Anja Bubke, Stefan Russo, Antal Rot, Reinhold Förster


  • CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues

    by Xiaobing Yu, Leonel Munoz-Sagredo, Karolin Streule, Patricia Muschong, Elisabeth Bayer, Romina Judith Walter, Julia Christine Gutjahr, Richard Greil, Miguel L. Concha, Carsten Müller-Tidow, et al.

    Acute myeloid leukemia (AML) has a poor prognosis under the current standard of care. In recent years, venetoclax, a BCL-2 inhibitor, was approved to treat patients who are ineligible for intensive induction chemotherapy. However, complete remission rates with venetoclax-based therapies are hampered by minimal residual disease (MRD) in a proportion of patients, leading to relapse. MRD is a result of leukemic stem cells being retained in bone marrow protective environments; activation of the CXCL12-CXCR4 pathway was shown to be relevant to this process. An important role is also played by cell adhesion molecules such as CD44, which has been shown to be crucial for the development of AML. Here we show that CD44 is involved in CXCL12 promotion of resistance to venetoclax-induced apoptosis in human AML cell lines and AML patient samples, which could be abrogated by CD44 knock down, knockout, or blocking with an anti-CD44 antibody. Split-Venus bimolecular fluorescence complementation showed that CD44 and CXCR4 physically associate at the cell membrane upon CXCL12 induction. In the venetoclax-resistant OCI-AML3 cell line, CXCL12 promoted an increase in the proportion of cells expressing high levels of embryonic stem cell core transcription factors (ESC-TFs: Sox2, Oct4, Nanog) abrogated by CD44 knockdown. This ESC-TF–expressing subpopulation which could be selected by venetoclax treatment, exhibited a basally enhanced resistance to apoptosis and expressed higher levels of CD44. Finally, we developed a novel AML xenograft model in zebrafish, which showed that CD44 knockout sensitizes OCI-AML3 cells to venetoclax treatment in vivo. Our study shows that CD44 is a potential molecular target for sensitizing AML cells to venetoclax-based therapies.


  • Open Access

    CD44 engagement enhances acute myeloid leukemia cell adhesion to the bone marrow microenvironment by increasing VLA-4 avidity

    by Julia C. Gutjahr, Elisabeth Bayer, Xiaobing Yu, Julia M. Laufer, Jan P. Höpner, Suzana Tesanovic, Andrea Härzschel, Georg Auer, Tanja Rieß, Astrid Salmhofer, et al.

    Adhesive properties of leukemia cells shape the degree of organ infiltration and the extent of leukocytosis. CD44 and the integrin VLA-4, a CD49d/CD29 heterodimer, are important factors of progenitor cell adhesion in bone marrow (BM). Here, we report their cooperation in acute myeloid leukemia (AML) by a novel non-classical CD44-mediated way of inside-out VLA-4 activation. In primary AML BM samples from patients and the OCI-AML3 cell line, CD44 engagement by hyaluronan induced inside-out activation of VLA-4 resulting in enhanced leukemia cell adhesion on VCAM-1. This was independent from VLA-4 affinity regulation but based on ligand-induced integrin clustering on the cell surface. CD44-induced VLA-4 activation could be inhibited by the Src family kinase inhibitor PP2 and the multikinase inhibitor midostaurin. In further consequence, the increased adhesion on VCAM-1 allowed AML cells to strongly bind stromal cells. Thereby VLA-4/VCAM-1 interaction promoted activation of Akt, MAPK, NF-kB and mTOR signaling and decreased AML cell apoptosis. Collectively, our investigations provide a mechanistic description of an unusual CD44 function in regulating VLA-4 avidity in AML, supporting AML cell retention in the supportive BM microenvironment.


  • Open Access

    TCL1 transgenic mice as a model for CD49d-high chronic lymphocytic leukemia

    by Eva Szenes, Andrea Härzschel, Sarah Decker, Erika Tissino, Justine Pischeli, Julia Christine Gutjahr, Sandra Kissel, Sandra Pennisi, Jan Philip Höpner, Alexander Egle, et al.


  • Open Access

    Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia

    by Julia C. Gutjahr, Eva Szenes, Lisa Tschech, Daniela Asslaber, Michaela Schlederer, Simone Roos, Xiaobing Yu, Tamara Girbl, Christina Sternberg, Alexander Egle, et al.

    Key Points: The spleen but not bone marrow microenvironment induces CD44v6 variants in CLL, which promote early engraftment. CD44v6 expression is linked to NF-κB and MAPK signaling in murine and human B-cell leukemia and contributes to proliferation.


  • Open Access

    Functional and clinical relevance of VLA-4 (CD49d/CD29) in ibrutinib-treated chronic lymphocytic leukemia

    by Erika Tissino, Dania Benedetti, Sarah E.M. Herman, Elisa Ten Hacken, Inhye E. Ahn, Kari G. Chaffee, Francesca Maria Rossi, Michele Dal Bo, Pietro Bulian, Riccardo Bomben, et al.

    The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib, which antagonizes B cell receptor (BCR) signals, demonstrates remarkable clinical activity in chronic lymphocytic leukemia (CLL). The lymphocytosis experienced by most patients under ibrutinib has previously been attributed to inhibition of BTK-dependent integrin and chemokine cues operating to retain the tumor cells in nodal compartments. Here, we show that the VLA-4 integrin, as expressed by CD49d-positive CLL, can be inside-out activated upon BCR triggering, thus reinforcing the adhesive capacities of CLL cells. In vitro and in vivo ibrutinib treatment, although reducing the constitutive VLA-4 activation and cell adhesion, can be overcome by exogenous BCR triggering in a BTK-independent manner involving PI3K. Clinically, in three independent ibrutinib-treated CLL cohorts, CD49d expression identifies cases with reduced lymphocytosis and inferior nodal response and behaves as independent predictor of shorter progression-free survival, suggesting the retention of CD49d-expressing CLL cells in tissue sites via activated VLA-4. Evaluation of CD49d expression should be incorporated in the characterization of CLL undergoing therapy with BCR inhibitors.